Phase IV Commitments Should Be Enforced By Civil Penalties, Not Withdrawal
Executive Summary
FDA expects to propose civil monetary penalties as one enforcement option for companies failing to fulfill postmarketing commitments, in lieu of removing the drug from the market.
You may also be interested in...
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization
Phase IV Protocol Submissions Should Not Have Time Limits, Merck Tells FDA
FDA should not impose time limits on submission of protocols for postmarketing studies, Merck's comments on FDA's draft guidance on postmarketing study status reports say.